OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sekeres on Staging Low- Versus High-Risk MDS

August 19th 2020

Mikkael A. Sekeres, MD, discusses staging patients with myelodysplastic syndromes.

Dr. Pavlick on Longer Follow-Up Data With Cemiplimab in CSCC

August 19th 2020

Anna C. Pavlick, DO, discusses the longer follow-up of the phase 2 EMPOWER-CSCC-1 study with cemiplimab in cutaneous squamous cell carcinoma.

Dr. Atlas on the Promise of Up-Front Cemiplimab in Locally Advanced CSCC

August 19th 2020

Jennifer L. Atlas, MD, discusses the promise of cemiplimab in the treatment of patients with locally advanced cutaneous squamous cell carcinoma.

Dr. Sam on Mitigating Risk of COVID-19 in Elderly Patients With Cancer

August 19th 2020

Christine Sam, MD, discusses strategies to mitigate the risk of the coronavirus disease 2019 in elderly patients with cancer.

Dr. Saba on Emerging Sequencing Strategies in Head and Neck Cancer

August 19th 2020

Nabil F. Saba, MD, FACP, discusses emerging sequencing strategies in head and neck cancer.

Dr. Cuellar on Concerns With Extrapolating Data for Biosimilars

August 19th 2020

Sandra Cuellar, PharmD, BCOP, discusses challenges with data extrapolation for biosimilars.

Dr. Yardley on Challenges With Resistance Mechanisms in HR+/HER2- Breast Cancer

August 19th 2020

Denise Yardley, MD, discusses challenges with resistance mechanisms in hormone receptor–positive, HER2-negative breast cancer.

Dr. D'Amato on the Utility of NGS in Stage I, II, and III Sarcoma

August 19th 2020

Gina Z. D'Amato, MD, discusses the utility of next-generation sequencing in patients with stage I, II, or III sarcoma.

Dr. Hamilton on the Promise of Tucatinib in HER2+ Breast Cancer Brain Metastases

August 18th 2020

Erika P. Hamilton, MD, discusses updated data from the phase 2 HER2CLIMB trial examining tucatinib in patients with HER2-positive breast cancer and brain metastases.

Dr. Ghosh on Differences Among Available BTK Inhibitors in B-Cell Malignancies

August 18th 2020

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.

Dr. O’Shaughnessy on the Utility of Tucatinib in the HER2+ Breast Cancer Brain Metastases

August 18th 2020

Joyce A. O'Shaughnessy, MD, discusses the utility of tucatinib in HER2-positive breast cancer with brain metastases.

Dr. Reardon on the Potential Utility of INO-5401 and INO-9012 in Glioblastoma

August 18th 2020

David A. Reardon, MD, discusses the role of INO-5401 and INO-9012 in glioblastoma.

Dr. Mirza on Safety Profile of Niraparib/Bevacizumab in Recurrent Ovarian Cancer

August 18th 2020

Mansoor Raza Mirza, MD, discusses the safety profile of niraparib in combination with bevacizumab in platinum-sensitive recurrent ovarian cancer.

Dr. Bunn on Targeting HER3 in NSCLC

August 18th 2020

Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.

Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

August 18th 2020

Erika P. Hamilton, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Dr. Pagel on Challenges With ASCT in Relapsed/Refractory DLBCL

August 18th 2020

John M. Pagel, MD, PhD, discusses challenges with autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Nowakowski on the Rationale for Reevaluating Enzastaurin in DLBCL

August 18th 2020

Grzegorz S. Nowakowski, MD, discusses the rationale for reevaluating the PCKß inhibitor enzastaurin in diffuse large B-cell lymphoma.

Dr. Wong on the Potential Role of Venetoclax in Relapsed/Refractory AL Amyloidosis

August 18th 2020

Sandy Wong, MD, discusses the potential role of venetoclax in relapsed/refractory light chain amyloidosis.

Dr. Weber on Emerging Therapies in Melanoma

August 17th 2020

Jeffrey S. Weber, MD, PhD, discusses emerging therapies in melanoma.

Dr. Welslau on the Benefits of Biosimilars in DLBCL

August 17th 2020

Manfred Welslau, MD, discusses the potential benefits of using biosimilars in diffuse large B-cell lymphoma.